Back to Resources
JOURNAL
Ibrutinib and Venetoclax Under Investigation as First-Line Combo in MCL
The combination of ibrutinib and venetoclax will be tested as frontline therapy in previously untreated patients with mantle cell lymphoma as part of the 3-part phase 3 SYMPATICO trial.
I'm interested in this
Share with others
Write the first review
Join now
to leave a review or read peer reviews!